Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)

Scott R. Evans, Daniel Rubin, Dean Follmann, Gene Pennello, W Charles Huskins, John H. Powers, David Schoenfeld, Christy Chuang-Stein, Sara E. Cosgrove, Vance G. Fowler, Ebbing Lautenbach, Henry F. Chambers

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Clinical trials that compare strategies to optimize antibiotic use are of critical importance but are limited by competing risks that distort outcome interpretation, complexities of noninferiority trials, large sample sizes, and inadequate evaluation of benefits and harms at the patient level. The Antibacterial Resistance Leadership Group strives to overcome these challenges through innovative trial design. Response adjusted for duration of antibiotic risk (RADAR) is a novel methodology utilizing a superiority design and a 2-step process: (1) categorizing patients into an overall clinical outcome (based on benefits and harms), and (2) ranking patients with respect to a desirability of outcome ranking (DOOR). DOORs are constructed by assigning higher ranks to patients with (1) better overall clinical outcomes and (2) shorter durations of antibiotic use for similar overall clinical outcomes. DOOR distributions are compared between antibiotic use strategies. The probability that a randomly selected patient will have a better DOOR if assigned to the new strategy is estimated. DOOR/RADAR represents a new paradigm in assessing the risks and benefits of new strategies to optimize antibiotic use.

Original languageEnglish (US)
Pages (from-to)800-806
Number of pages7
JournalClinical Infectious Diseases
Volume61
Issue number5
DOIs
StatePublished - 2015

Fingerprint

Anti-Bacterial Agents
Patient Harm
Sample Size
Clinical Trials

Keywords

  • Antibiotic use strategies
  • DOOR
  • RADAR

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). / Evans, Scott R.; Rubin, Daniel; Follmann, Dean; Pennello, Gene; Huskins, W Charles; Powers, John H.; Schoenfeld, David; Chuang-Stein, Christy; Cosgrove, Sara E.; Fowler, Vance G.; Lautenbach, Ebbing; Chambers, Henry F.

In: Clinical Infectious Diseases, Vol. 61, No. 5, 2015, p. 800-806.

Research output: Contribution to journalArticle

Evans, SR, Rubin, D, Follmann, D, Pennello, G, Huskins, WC, Powers, JH, Schoenfeld, D, Chuang-Stein, C, Cosgrove, SE, Fowler, VG, Lautenbach, E & Chambers, HF 2015, 'Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)', Clinical Infectious Diseases, vol. 61, no. 5, pp. 800-806. https://doi.org/10.1093/cid/civ495
Evans, Scott R. ; Rubin, Daniel ; Follmann, Dean ; Pennello, Gene ; Huskins, W Charles ; Powers, John H. ; Schoenfeld, David ; Chuang-Stein, Christy ; Cosgrove, Sara E. ; Fowler, Vance G. ; Lautenbach, Ebbing ; Chambers, Henry F. / Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). In: Clinical Infectious Diseases. 2015 ; Vol. 61, No. 5. pp. 800-806.
@article{d8411a952df94ece952a00b10e74124d,
title = "Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)",
abstract = "Clinical trials that compare strategies to optimize antibiotic use are of critical importance but are limited by competing risks that distort outcome interpretation, complexities of noninferiority trials, large sample sizes, and inadequate evaluation of benefits and harms at the patient level. The Antibacterial Resistance Leadership Group strives to overcome these challenges through innovative trial design. Response adjusted for duration of antibiotic risk (RADAR) is a novel methodology utilizing a superiority design and a 2-step process: (1) categorizing patients into an overall clinical outcome (based on benefits and harms), and (2) ranking patients with respect to a desirability of outcome ranking (DOOR). DOORs are constructed by assigning higher ranks to patients with (1) better overall clinical outcomes and (2) shorter durations of antibiotic use for similar overall clinical outcomes. DOOR distributions are compared between antibiotic use strategies. The probability that a randomly selected patient will have a better DOOR if assigned to the new strategy is estimated. DOOR/RADAR represents a new paradigm in assessing the risks and benefits of new strategies to optimize antibiotic use.",
keywords = "Antibiotic use strategies, DOOR, RADAR",
author = "Evans, {Scott R.} and Daniel Rubin and Dean Follmann and Gene Pennello and Huskins, {W Charles} and Powers, {John H.} and David Schoenfeld and Christy Chuang-Stein and Cosgrove, {Sara E.} and Fowler, {Vance G.} and Ebbing Lautenbach and Chambers, {Henry F.}",
year = "2015",
doi = "10.1093/cid/civ495",
language = "English (US)",
volume = "61",
pages = "800--806",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)

AU - Evans, Scott R.

AU - Rubin, Daniel

AU - Follmann, Dean

AU - Pennello, Gene

AU - Huskins, W Charles

AU - Powers, John H.

AU - Schoenfeld, David

AU - Chuang-Stein, Christy

AU - Cosgrove, Sara E.

AU - Fowler, Vance G.

AU - Lautenbach, Ebbing

AU - Chambers, Henry F.

PY - 2015

Y1 - 2015

N2 - Clinical trials that compare strategies to optimize antibiotic use are of critical importance but are limited by competing risks that distort outcome interpretation, complexities of noninferiority trials, large sample sizes, and inadequate evaluation of benefits and harms at the patient level. The Antibacterial Resistance Leadership Group strives to overcome these challenges through innovative trial design. Response adjusted for duration of antibiotic risk (RADAR) is a novel methodology utilizing a superiority design and a 2-step process: (1) categorizing patients into an overall clinical outcome (based on benefits and harms), and (2) ranking patients with respect to a desirability of outcome ranking (DOOR). DOORs are constructed by assigning higher ranks to patients with (1) better overall clinical outcomes and (2) shorter durations of antibiotic use for similar overall clinical outcomes. DOOR distributions are compared between antibiotic use strategies. The probability that a randomly selected patient will have a better DOOR if assigned to the new strategy is estimated. DOOR/RADAR represents a new paradigm in assessing the risks and benefits of new strategies to optimize antibiotic use.

AB - Clinical trials that compare strategies to optimize antibiotic use are of critical importance but are limited by competing risks that distort outcome interpretation, complexities of noninferiority trials, large sample sizes, and inadequate evaluation of benefits and harms at the patient level. The Antibacterial Resistance Leadership Group strives to overcome these challenges through innovative trial design. Response adjusted for duration of antibiotic risk (RADAR) is a novel methodology utilizing a superiority design and a 2-step process: (1) categorizing patients into an overall clinical outcome (based on benefits and harms), and (2) ranking patients with respect to a desirability of outcome ranking (DOOR). DOORs are constructed by assigning higher ranks to patients with (1) better overall clinical outcomes and (2) shorter durations of antibiotic use for similar overall clinical outcomes. DOOR distributions are compared between antibiotic use strategies. The probability that a randomly selected patient will have a better DOOR if assigned to the new strategy is estimated. DOOR/RADAR represents a new paradigm in assessing the risks and benefits of new strategies to optimize antibiotic use.

KW - Antibiotic use strategies

KW - DOOR

KW - RADAR

UR - http://www.scopus.com/inward/record.url?scp=84942023902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942023902&partnerID=8YFLogxK

U2 - 10.1093/cid/civ495

DO - 10.1093/cid/civ495

M3 - Article

C2 - 26113652

AN - SCOPUS:84942023902

VL - 61

SP - 800

EP - 806

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 5

ER -